Literature DB >> 7902708

A structural polymorphism of human dopamine D2 receptor, D2(Ser311-->Cys).

M Itokawa1, T Arinami, N Futamura, H Hamaguchi, M Toru.   

Abstract

No structural change of the dopamine D2 receptor (DRD2) has been reported so far, though the DRD2 gene has been suggested to be one of the candidate genes for mental disorders. Herein we report one missense nucleotide mutation from C to G resulting in a substitution of serine with cystein at the codon 311 located in the third intracellular loop of the DRD2 that was found in the analyses of the sequence of the DRD2 gene in 50 schizophrenics. The allele frequency, 0.04, of this Cys311 allele in 50 schizophrenics was slightly increased compared with that, 0.023, in 110 controls though the difference was not significant. The schizophrenics with Cys311 tended to have a lower age of onset and a positive family history of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902708     DOI: 10.1006/bbrc.1993.2404

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  21 in total

Review 1.  Novel dopamine D2 receptor signaling through proteins interacting with the third cytoplasmic loop.

Authors:  Kohji Fukunaga; Norifumi Shioda
Journal:  Mol Neurobiol       Date:  2011-12-20       Impact factor: 5.590

Review 2.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

3.  Genetic susceptibility to Parkinson's disease among South and North Indians: I. Role of polymorphisms in dopamine receptor and transporter genes and association of DRD4 120-bp duplication marker.

Authors:  Ramesh C Juyal; Mitashree Das; Sohan Punia; Madhuri Behari; Geetika Nainwal; Sumit Singh; Pazhayannur V Swaminath; Shyla T Govindappa; Sachi Jayaram; Uday B Muthane; B K Thelma
Journal:  Neurogenetics       Date:  2006-07-01       Impact factor: 2.660

4.  Dopamine D2 receptor polymorphisms and susceptibility to alcohol dependence in Indian males: a preliminary study.

Authors:  Pushplata Prasad; Atul Ambekar; Meera Vaswani
Journal:  BMC Med Genet       Date:  2010-02-11       Impact factor: 2.103

5.  D1 and D2 dopamine receptor-mediated inhibition of activated normal T cell proliferation is lost in jurkat T leukemic cells.

Authors:  Biswarup Basu; Chandrani Sarkar; Debanjan Chakroborty; Subhalakshmi Ganguly; Saurav Shome; Partha Sarathi Dasgupta; Sujit Basu
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

6.  The Cys allele of the DRD2 Ser311Cys polymorphism has a dominant effect on risk for schizophrenia: evidence from fixed- and random-effects meta-analyses.

Authors:  Stephen J Glatt; Erik G Jönsson
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2006-03-05       Impact factor: 3.568

7.  Analysis of transmission of novel polymorphisms in the somatostatin receptor 5 (SSTR5) gene in patients with autism.

Authors:  Marlene B Lauritsen; Mette Nyegaard; Catalina Betancur; Catherine Colineaux; Trine L Josiassen; Torben A Kruse; Marion Leboyer; Henrik Ewald
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2003-08-15       Impact factor: 3.568

8.  Pharmacological analysis of human D1 AND D2 dopamine receptor missense variants.

Authors:  Munya A Al-Fulaij; Yong Ren; Martin Beinborn; Alan S Kopin
Journal:  J Mol Neurosci       Date:  2008-01-18       Impact factor: 3.444

9.  Family-based association testing strongly implicates DRD2 as a risk gene for schizophrenia in Han Chinese from Taiwan.

Authors:  S J Glatt; S V Faraone; J A Lasky-Su; T Kanazawa; H-G Hwu; M T Tsuang
Journal:  Mol Psychiatry       Date:  2008-03-11       Impact factor: 15.992

10.  Evolution of haplotypes at the DRD2 locus.

Authors:  C M Castiglione; A S Deinard; W C Speed; G Sirugo; H C Rosenbaum; Y Zhang; D K Grandy; E L Grigorenko; B Bonne-Tamir; A J Pakstis
Journal:  Am J Hum Genet       Date:  1995-12       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.